Plasma markers of COVID-19 severity: a pilot study

Respiratory Research

Table 3 Plasma levels of acute-phase protein in patients with different severity of COVID-19

APP	Moderate COVID-19	Severe COVID-19	p-value
ACT	1459 (1418–1726)	1392 (1309–1557)	p = 0.131
SAA	49.49 (45.33–55.58)	49.33 (44.85–50.56)	p = 0.597
AGP	150.0 (123.0–201.3)	173.5 (131.5–226.5)	p = 0.472
HP	253.0 (195.8–317.5)	271.5 (156.3–365.3)	p = 0.821
AAT	188.5 (150.3–253.3)	267.0 (227.0–327.3)	p = 0.013
hs-CRP	8.305 (0.716–13.88)	12.65 (6.883–20.56)	p = 0.226
A2MG	136.5 (106.0–164.0)	109.0 (105.9–126.5)	p = 0.225
CP	39.05 (35.83–46.50)	47.80 (34.90–54.18)	p = 0.273
ALB	3110 (2748–3640)	1930 (1825–2278)	p < 0.001

For all proteins (mg/dl), except for ACT and SAA (µg/ml). Data presented as median and interquartile range (IQR)
A2MG alpha2-macroglobulin, AAT alpha1-antitrypsin, ACT alpha 1-antichymotrypsin, AGP alpha-1 acid glycoprotein, ALB albumin, CP ceruloplasmin, hs-CRP high sensitivity C-reactive protein, HP haptoglobin, SAA serum amyloid A. Two-sided p-values were calculated with Mann–Whitney-U test. A p-value below 0.05 was considered as a significant. The number of independent samples was n = 10 in each group

ISSN: 1465-993X